Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The decisions of an individual about his food intake depend upon a variety of internal and external signals. The present contribution describes the physiological mechanisms controlling food intake to preserve body composition and performance. Centers within the hypothalamus including their connections to higher and lower structures within the central nervous system, especially to the limbic system, are involved in the control a food intake. Neuropeptides and neurotransmitters usually initiate more complex actions including the search for food and satiety phenomena. Their production and release are influenced by food consumption as well as intake of specific nutrients, sensorial perceptions, and a variety of other factors. Vagal reflexes and gastro-intestinal hormones, fat cell size, physical activity, and thermogenesis also influence perceptions of hunger and satiety. A model satisfactorily describing the interactions between all known factors that control food intake is still missing. The path from hunger to satiety could be described as sequences of cascades similar to the various steps in blood clotting. Control of food intake during early life dependably relies on energy requirement, and can be utilized for ad-libitum feeding. Obesity and anorexia nervosa are manifestations of disturbed control over food intake. Neuropharmacology offers several therapeutic approaches to specific conditions. However, by and large abnormalities of food intake control have to be treated by behavioral modification.
 ...
PMID:[Control of food intake]. 287 89

Increased opiate peptide concentrations in brain and plasma have been associated with increased feeding. The role of beta-endorphin in the control of food intake and obesity was examined by measuring concentrations in hypothalamus, pituitary and plasma of hungry (6-hr fasted) and satiated (5 min after a meal) Zucker obese and lean rats. beta-Endorphin concentrations (1) in satiated vs. hungry rats were increased in the VMH (90 vs. 79 pg/mg tissue, p less than 0.05) and decreased in the supraoptic nucleus (65 vs. 78 pg/mg tissue, p less than 0.05), (2) in obese vs. lean rats were decreased in the VMH (79 vs. 90 pg/mg tissue, p less than 0.05) and (3) in female vs. male rats were increased in the anterior hypothalamus (123 vs. 59 pg/mg tissue, p less than 0.01) and VMH (90 vs. 79 pg/mg tissue, p less than 0.05). Analysis of a phenotype by feeding condition interaction revealed that obese but not lean rats had higher beta-endorphin concentrations in the satiated vs. hunger condition. However, plasma beta-endorphin concentrations did not differ with feeding condition, phenotype or sex. Intermediate and posterior but not anterior pituitary beta-endorphin concentrations were lower in obese than lean rats. Thus, there is some evidence for a relationship between beta-endorphin concentration and feeding in the hypothalamus, but beta-endorphin concentrations in plasma do not appear to be influenced by feeding condition or obesity.
 ...
PMID:Meal-stimulated increased concentrations of beta-endorphin in the hypothalamus of Zucker obese and lean rats. 293 72

The effects of moderate dietary-fibre supplementation on satiety, energy intake and faecal energy excretion were studied in 20 young healthy volunteers of normal body weight, mean body mass index 20.9, receiving a dietary fibre supplement of 7.3 g per day in a randomized, double-blind, cross-over study. Hunger feeling, energy intake, and defaecation pattern, were recorded daily during a 2-week control period and then, during two 4-week treatment periods. Furthermore, faecal energy output was determined during the last week of each treatment period. The fibre treatment, as compared to placebo, resulted in a significantly higher faecal energy excretion: 173 kcal/d (163-183 kcal/d) vs 153 kcal/d (135-171 kcal/d), respectively (P less than 0.05); a decrease in hunger rating (using a visual analogue scale) (P less than 0.05); an increase in number of bowel movements (P less than 0.05), and a softer consistency of the stools (P less than 0.05). There was no significant difference in mean energy intake between the two treatment periods. This study demonstrated that moderate dietary fibre supplementation in normal man increases faecal energy excretion with simultaneously decreased hunger feeling. These beneficial effects may have therapeutic value in the management of obesity.
 ...
PMID:Effects of a moderate dietary fibre supplement on hunger rating, energy input and faecal energy output in young, healthy volunteers. A randomized, double-blind, cross-over trial. 303 28

Certain features of the body hormonal system participation in the realizing of the specific dynamic action of food (SDAF) were studied in 26 patients with exogenous constitutional obesity. The radioimmunoassay was used to estimate the levels of a number of hormones (gastrin, insulin, glucagon, triiodothyronine, thyrotrophin, adrenocorticotrophin and hydrocortisone) in the peripheral blood of the patients on an empty stomach (the basal level) and 1,2 and 4 hours after food protein intake. The control group consisted of 20 normal subjects. It has been shown that SDAF is a complex process of changing from the state of hunger to satiation that involves many regulatory components, both nervous and humoral. The study of the features of the SDAF development in health and disease presents valuable information on the mechanisms of metabolic disorders in the body in varying pathologic states including obesity.
 ...
PMID:[Specific dynamic action of food in obese patients]. 303 2

Three studies have been undertaken to investigate why there are individual differences in the response to d-fenfluramine with respect to food intake and hunger in the short term and on body weight loss in the long term. Fenfluramine and norfenfluramine plasma levels have been used as probes to help detect and normalize these variances. In a single dose ranging volunteer study (0, 30, 40, and 60 mg), d-fenfluramine levels were significantly related to caloric intake and hunger rating scales when compared individually, and the slopes of the regression lines showed intersubject variation. These slopes, an index of each subject's response to fenfluramine, appear to be related to both the percentage underweight and more weakly to the percentage overweight. Those subjects at the extremes of weight showed a greater response to a given drug level. In two placebo-controlled 3 month studies (30 mg/day), the variances in weight loss were not explained by steady state drug levels, the percentage overweight, initial weight, duration of obesity, or caloric intake even when weight loss was normalized for differences in drug levels. Age, however, was significantly related to weight loss, with each additional 10 years increasing weight loss by approximately 1 kg. If confirmed, the sensitivity of fenfluramine anorexia may be an objective acute test of the central control of food intake. However, in long term clinical studies, drug levels were only weakly related to weight loss and other undefined factors seem to determine which patients responded better to fenfluramine treatment.
 ...
PMID:Factors that may effect the reduction of hunger and body weight following d-fenfluramine administration. 305 14

Regional brain glucose utilization was investigated in lean and fatty Zucker rats when feeding status was changed. Ad-lib-fed fat rats exhibited lower glucose utilization in the central amygdala than ad-lib-fed lean rats. Food deprivation for 72 h enhanced glucose utilization in the ventromedial hypothalamus, lateral hypothalamic area of both phenotypes, hippocampus of fat rats, mammillary body and ventral tegmental area of leans. These results suggest association of the central amygdala with the development of genetic obesity and of the latter 5 areas with hunger-motivated behaviors.
 ...
PMID:Effect of food deprivation on regional brain glucose utilization in lean and fatty Zucker rats. 321 40

A number of peptides synthesized and secreted by gastrointestinal cells have been shown to possess significant effects on food intake and on perceptions of hunger and satiety in humans. In this paper, we review the available literature on these effects and emphasize the current obstacles for the therapeutic application of peptides to the problem of obesity.
 ...
PMID:The effect of gut peptides on hunger, satiety, and food intake in humans. 330 Apr 78

The Garren gastric bubble has recently been introduced as a new treatment for obesity. The technique entails endoscopic placement of a balloon intragastrically to help decrease hunger and cause the feeling of early satiety. Recently side effects and complications have been reported. This report describes a complication in which the balloon would not deploy from the introducer so it could not be removed or inflated. After multiple maneuvers, the gastric bubble was finally removed with no serious sequelae. It is possible if the balloon is loaded and passed without carefully aligning all the parts of the equipment that serious complications could result.
 ...
PMID:Partial deployment of the Garren gastric bubble: a new complication. 357 28

We studied eating behavior in two non-overlapping cohorts of consecutive patients electing gastric bypass surgery for obesity: 100 patients one year after operation and 60 patients three years afterward. Information was obtained through structured interviews and from office charts. Eating behavior was compared with previously collected data on 232 morbidly obese adults and 174 adults of normal weight. Despite an average weight loss of 100 lb (45 kg), there was little evidence of disturbed eating patterns among gastric bypass patients. Significantly fewer gastric bypass patients than morbidly obese comparison subjects reported frequent hunger, overeating, guilt about eating, or food preoccupation. Gastric bypass patients reported less preoccupation with food than did the normal-weight comparison subjects.
 ...
PMID:Eating behavior after gastric bypass surgery for obesity. 361 24

There is increasing evidence that peptides in the brain are important in the control of food intake. Administration of opioid and CCK peptides have elicited hunger and satiety, respectively. To evaluate the interaction of these peptides and their role in the central nervous system, concentrations of met-enkephalin were measured in the hypothalamus of rats following peripheral administration of CCK; in addition, effects of feeding and fasting and obesity were studied. In CCK- vs. saline-injected rats met-enkephalin concentrations were decreased in the paraventricular nucleus (PVN), suprachiasmatic nucleus (SC), supraoptic nucleus (SON), dorsomedial hypothalamus (DMH) and ventromedial hypothalamus (VMH). In fed compared with fasted rats met-enkephalin concentrations were higher in the anterior hypothalamus (AH) and lower in the SC; in obese compared with lean rats, concentrations were higher in the AH, PVN, SC, SON, DMH, lateral hypothalamus and VMH. These results show that peripheral injections of CCK can decrease concentrations of met-enkephalin in the brain and suggest a mechanism by which these peptides may interact to influence behavior. In addition, the findings support the hypothesis that the hyperphagia which is typical of obese rats may be due to increased concentrations of met-enkephalin.
 ...
PMID:Changes in brain met-enkephalin concentrations with peripheral CCK injections in Zucker rats. 371 42


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>